Key Points
- Major shareholder Chidozie Ugwumba sold 5,559 shares on Feb. 3 at $4.10 and has disposed of roughly 92,375 shares in a recent multi-day selling spree, leaving him with about 550,000 shares (a ~1% ownership decline).
- Clene stock traded near $4.07 with a market cap of ~$44M and negative earnings; despite this, analysts hold a consensus rating of "Moderate Buy" with a consensus target price of $32.60.
Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 5,559 shares of Clene stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $4.10, for a total transaction of $22,791.90. Following the completion of the sale, the insider owned 550,000 shares in the company, valued at approximately $2,255,000. This represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Monday, February 2nd, Chidozie Ugwumba sold 3,800 shares of Clene stock. The shares were sold at an average price of $4.04, for a total transaction of $15,352.00.
- On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The stock was sold at an average price of $4.13, for a total value of $23,483.18.
- On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The shares were sold at an average price of $4.32, for a total value of $66,026.88.
- On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The stock was sold at an average price of $4.91, for a total transaction of $42,800.47.
- On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The stock was sold at an average price of $5.08, for a total transaction of $21,026.12.
- On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The shares were sold at an average price of $5.02, for a total value of $32,218.36.
- On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The stock was sold at an average price of $5.27, for a total transaction of $29,280.12.
- On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The stock was sold at an average price of $5.32, for a total transaction of $67,377.80.
- On Wednesday, January 21st, Chidozie Ugwumba sold 12,119 shares of Clene stock. The shares were sold at an average price of $5.05, for a total value of $61,200.95.
- On Tuesday, January 20th, Chidozie Ugwumba sold 12,432 shares of Clene stock. The shares were sold at an average price of $4.80, for a total transaction of $59,673.60.
Clene Stock Performance
CLNN stock traded up $0.15 during midday trading on Friday, reaching $4.07. The stock had a trading volume of 17,007 shares, compared to its average volume of 111,336. Clene Inc. has a 52-week low of $2.28 and a 52-week high of $13.50. The stock has a market cap of $44.16 million, a PE ratio of -1.20 and a beta of 0.81. The firm has a fifty day simple moving average of $5.89 and a two-hundred day simple moving average of $6.53.
Clene (NASDAQ:CLNN - Get Free Report) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. On average, sell-side analysts predict that Clene Inc. will post -5.19 EPS for the current fiscal year.
Institutional Investors Weigh In On Clene
Hedge funds and other institutional investors have recently modified their holdings of the stock. Jones Financial Companies Lllp purchased a new stake in shares of Clene in the third quarter valued at about $29,000. Jane Street Group LLC acquired a new position in shares of Clene in the 2nd quarter valued at $47,000. Lunt Capital Management Inc. grew its position in Clene by 71.2% during the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company's stock valued at $199,000 after acquiring an additional 21,217 shares during the period. Finally, Scoggin Management LP raised its holdings in Clene by 42.8% in the second quarter. Scoggin Management LP now owns 142,750 shares of the company's stock valued at $558,000 after buying an additional 42,750 shares during the period. 23.28% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms have commented on CLNN. UBS Group reiterated a "buy" rating on shares of Clene in a report on Wednesday, December 3rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Clene in a research report on Friday, January 9th. D. Boral Capital reiterated a "buy" rating and set a $23.00 price target on shares of Clene in a research note on Friday, January 9th. Finally, Benchmark restated a "buy" rating on shares of Clene in a report on Thursday, December 4th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Clene has a consensus rating of "Moderate Buy" and a consensus target price of $32.60.
Check Out Our Latest Analysis on CLNN
Clene Company Profile
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
